NewcelX prices $1.55 million private placement at 20% premium to market
NCEL•NewcelX entered agreements for a $1.55 million private placement of 471,125 shares at $3.29 each, a 20% premium to the November 6, 2026, closing price. Proceeds will primarily advance its diabetes program NCEL-101.
1. Placement details
The sale includes 471,125 common shares priced at $3.29 each and warrants covering 353,344 shares, exercisable at $3.75 per share. Closing is expected on or about November 23, 2026, subject to customary conditions. Proceeds will primarily fund IND-enabling studies and preparations for a planned Phase 1/2a trial of NCEL-101 in 2027.
